News from zydus cadila A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Mar 05, 2020, 11:19 ET Zydus Announces World's First Drug for the Treatment of Non-Cirrhotic NASH

Saroglitazar, approved by DCGI becomes the first ever drug anywhere in the world for treatment of Non-Cirrhotic Non-Alcoholic SteatoHepatitis (NASH)...


Oct 03, 2019, 08:00 ET Zydus Announces Positive Results From EVIDENCES IV Phase 2 Clinical Trial of Saroglitazar Magnesium in NAFLD and NASH

Zydus Cadila, an innovation-driven, global pharmaceutical company, announced that Saroglitazar Magnesium has achieved the primary end-points in the...


Jun 17, 2019, 10:28 ET Zydus Announces Completion of Enrolment in EVIDENCES IV Phase 2 Clinical Trial of Saroglitazar Magnesium in NASH

Zydus Cadila, an innovation-driven, global pharmaceutical company, announced that it has completed enrolment of 104 patients with Non-Alcoholic Fatty ...


Nov 10, 2017, 06:12 ET Zydus Announces Regulatory Approval of Lipaglyn™ (Saroglitazar Magnesium) in Mexico

Approval to commercialize Lipaglyn™ (Saroglitazar Magnesium) in Mexico for treatment of: Dyslipidemia in patients with diabetes mellitus type 2....


Oct 31, 2016, 07:57 ET Zydus to Present New Scientific Data of Investigational Saroglitazar at the 2016 AASLD Liver Meeting in Boston, USA

Zydus Cadila today announced that new data of Saroglitazar will be presented at The Liver Meeting® being held at the John B. Hynes Veterans Memorial...


Jun 11, 2016, 12:59 ET New Scientific Data of Investigational Lipaglyn[TM] (Saroglitazar), and Real World Data in Patients will be Featured at American Diabetes Association (ADA) 76th Scientific Sessions

Zydus Cadila today announced that new data on Saroglitazar have been selected for presentations at the 76th Annual Scientific Sessions of the...


Jun 06, 2015, 10:00 ET Zydus to Present New Scientific Data on Lipaglyn (Saroglitazar), and Real World Data in Patients With Type 2 Diabetes at the American Diabetes Association 75th Scientific Sessions in Boston, USA

Zydus Cadila, a leading global healthcare provider, today announced that new scientific and clinical data on Saroglitazar will be presented at the...


Apr 23, 2015, 04:27 ET Zydus Group to Donate USD 240,000 to The National Institutes of Health, USA for Advancing Leishmaniasis Research

Etna Biotech, the Vaccine R & D subsidiary of Zydus, announced a collaborative program with the National Institute of Allergy and Infectious...


Dec 09, 2014, 04:34 ET A Zydus lança o primeiro biossimilar do Adalimumab do mundo

Após uma espera de mais de uma década, a terapia revolucionária, que proporcionou uma nova chance para milhões de pacientes no mundo sofrendo de...


Dec 09, 2014, 04:32 ET Zydus lanza el primer biosimilar de Adalimumab en el mundo

Luego de esperar más de una década, la revolucionaria terapia que proporcionó una nueva esperanza de vida a millones de pacientes de todo el mundo...


Dec 09, 2014, 04:25 ET Zydus bringt weltweit erstes Biosimilar von Adalimumab auf den Markt

Therapiezugang hat Auswirkungen für 12 Millionen Patienten mit Autoimmunerkrankungen wie rheumatoide Arthritis, juvenile idiopathische Arthritis,...


Dec 09, 2014, 04:24 ET Zydus lanza el primer biosimilar mundial de Adalimumab

El acceso a esta terapia impactará a 12 millones de personas que padecen enfermedades auto-inmunes como la artritis reumatoide, artritis idopática...


Dec 09, 2014, 04:22 ET Zydus lance le premier biosimilaire d'adalimumab au monde

L'accès à ce traitement aura des incidences sur 12 millions de personnes atteintes de maladies auto-immunes comme la polyarthrite rhumatoïde,...


Dec 09, 2014, 04:17 ET Zydus Launches World's First Biosimilar of Adalimumab

Access to this therapy will impact 12 million people suffering from auto immune disorders like rheumatoid arthritis, juvenile idiopathic arthritis,...